After investing half a billion DKK in promising new antibiotics, Novo Holdings keeps its powder dry to secure funds for follow-up investments
If you’re a biotech company with a potential treatment for antibiotic resistance in the development pipeline and you were hoping to receive financial support from the Novo Nordisk Foundation’s antibiotic Repair Impact Fund, you’ll have to be patient.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.